Converge Bio

Converge Bio is redefining the intersection of biology and artificial intelligence. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs, faster leveraging the power of Generative AI and Large Language Models (LLMs) trained on biological languages.

Foundation models and researchHealth and bio

Converge Bio raised $25M in a Series A round announced January 13, 2026, according to techcrunch.com. Investors in that round: Bessemer Venture Partners.

Raise history

1. September 29, 2026
   First seen by Recent Funding
   via startups.gallery
2. January 13, 2026
   Series A · $25M
   BBessemer Venture Partners (lead)
   Source: techcrunch.com (startups.gallery listing)

Investors

• BBessemer Venture Partners

Related other companies

• QQuartermaster$140M · Sep 28, 2026
• SSnorkel AI$350M · Sep 23, 2026
• EEnveda$311M · Sep 23, 2026
• HHeidi Health$100M · Sep 22, 2026
• FFirecrawl$75M · Sep 22, 2026
• CCorridor$25M · Sep 21, 2026
• JJack & Jill$40M · Sep 19, 2026
• MMithr Inc.$20M · Sep 19, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/converge-bio.